Liver biopsy in NASH clinical trials by Prof. P. Bedossa
Prof. Pierre Bedossa (France) exploring mandatory role liver biopsy plays in clinical trials for NASH and the need for a central pathologist.
NASH Observatory
⏿ The PanNASH Initiative is an interactive web-based platform presenting global NASH statistics to inform NASH control and research.
Read MoreLiver biopsy in NASH clinical trials by Prof. P. Bedossa
Association of serum vitamin D level and nonalcoholic fatty liver disease: a meta-analysis.
T. Liu et al. aimed to explore the potential link of serum vitamin D level with NAFLD. Of the 309 initially retrieved studies, 15 studies of high quality involving a total of 20 096 participants (including 7803 NAFLD patients) were included in this meta-analysis. Meta-analysis of continuous data indicated that NAFLD patients...
Role of PPARs (experimental paper) by Prof. F. Tacke
Prof. Frank Tacke discusses a paper in press in the Journal of Hepatology regarding the role of PPAR’s in experimental models and how these PPAR’s affect the progression of liver disease.
NAFLD: time to update the terminology? By Prof. S. Francque
2020 started with an important discussion about the terminology to be used regarding Non Alcoholic Fatty Liver Disease (NAFLD). In this exclusive interview for the PanNASH web site, Prof Sven Francque discusses the rationale of this change and the possible impact in clinical practice
Vitamin E is an effective treatment for nonalcoholic steatohepatitis in HIV mono-infected patients.
Liver disease is common among patients infected with HIV. The proportion of deaths caused by liver-related aetiologies has increased between 8 to 10-fold in the post-antiretroviral therapy (ART) era while AIDS-related mortality has fallen more than 90-fold. NAFLD is an important contributor to this trend. Higher rates of the...
Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196).
Hypothyroidism has been linked to certain elements of the metabolic syndrome such as obesity and dyslipidemia which may explain its association with NAFLD. The pathogenesis of NAFLD might be partly attributed to a state of relative intra-hepatic hypothyroidism, a condition of decreased liver thyroid hormone levels. Although...
NASH and NAFL: it is not only about liver but it is a complex inter-organ crosstalk in which adipose tissue dysfunction is an important driver of the disease.
In this Expert perspective video, Prof Sven Francque explains how to make the distinction between NAFL and NASH. This is important even though in clinical practice there is a continuum between the two. In the pathophysiology of NASH there is a complex interplay between different organs. Adipose tissue dysfunction is an important driver of disease.
Treatment of nonalcoholic fatty liver disease: from adult trials to perspectives in the management of children and adolescents.
This editorial discusses how results from clinical trials in adult NAFLD patients can be translated to improved therapies of NAFLD in children and adolescents.
Diet quality and its association with nonalcoholic fatty liver disease and all-cause and cause-specific mortality.
Healthy diet has been recommended for NAFLD, although it is not clear whether improving diet quality can prevent mortality. ER Yoo et al. aim to assess the impact of quality of diet on NAFLD and mortality in subjects with and without NAFLD. High diet quality was inversely associated with NAFLD and was positively associated...
NAFLD: a hegemonic disease by Prof. S. Francque
In this Expert perspective video, Prof Sven Francque explains how to make the distinction between NAFL and NASH. This is important even though in clinical practice there is a continuum between the two. In the pathophysiology of NASH there is a complex interplay between different organs. Adipose tissue dysfunction is an important driver of disease.
The molecular basis for current targets of NASH therapies.
Metabolic substrate overload, insulin resistance, lipotoxicity, endoplasmic reticulum stress, inflammasome activation, inflammation, hepatocyte death, and fibrogenesis represent a potential target area of therapy and many are now being evaluated in preclinical studies as well as phase 1, 2, and 3 clinical trials...
Association between non-alcoholic fatty liver disease and risk of new-onset atrial fibrillation in healthy adults.
Previous studies demonstrated conflicting results regarding the association between non-alcoholic fatty liver disease (NAFLD) and atrial fibrillation (AF). The statistical power was not sufficient because of modest sample sizes of these studies. We analyzed a large population-based cohort to evaluate the association between NAFLD and AF...